OHSU IIT: A Phase II, Open-Label, Study of Olaparib in combination with either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib monotherapy in Patients with Metastatic Triple-Negative Breast Cancer
The purpose of this study is to see if we can lower the chance of breast cancer growing, or spreading, by treating participants with a combination of a PARP inhibitor (Olaparib) and an immune therapy (Durvalumab) or Olaparib and a MEK inhibitor (Selumetinib) or Olaparib and a AKT inhibitor (Capivasertib or a ATR inhibitor Ceralaser alone . We also want to learn more about how participants tumors respond to this treatment by performing clinical tests on biopsied tumor tissue.
Metastatic Triple Negative Breast Cancer
18 Years and older females
Biopsy proven metastatic TNBC
No prior PARP inhibitor exposure, no prior immunomodulatory drug exposure
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug for 13 cycles (approximately 52 weeks). If your cancer does not get worse and you do not have bad side effects the investigator may have you continue the study drug for longer than 13 cycles. After you finish study drug the investigator and/or study team will continue to watch you for side effects and follow your condition either with follow-up clinic visits or follow-up phone calls every 6 months for one year until the study has been completed.
Knight Cancer Institute Clinical Trials
OHSU Knight Cancer Institute